Skip to Content
Merck
  • Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.

Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.

Biochemical and biophysical research communications (2015-01-17)
Yunxia Lu, Jingjing Cheng, Li Chen, Chaofei Li, Guanjun Chen, Li Gui, Bing Shen, Qiu Zhang
ABSTRACT

Fenofibrate (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley rats were divided into standard chow diets (SCD), high-fat diets (HFD) and HFD plus FF treatment group (HFD + FF) randomly. The rats of latter two groups were given HFD feeding for 5 months, then HFD + FF rats were treated with FF (30 mg/kg, once daily) via gavage for another 2 months. The pathological and tensional changes, protein expression of eNOS, and ER stress related genes in thoracic aorta were measured. Then impacts of palmitic acid (PA) and FF on EDV of thoracic aorta from normal female SD rats were observed. Ultimately the expression of ER stress related genes were assessed in primary mouse aortic endothelial cells (MAEC) treated by fenofibric acid (FA) and PA. We found that FF treatment improved serum lipid levels and pathological changes in thoracic aorta, accompanied with decreased ER stress and increased phosphorylation of eNOS. FF pretreatment also improved EDV impaired by different concentrations of PA treatment. The dose- and time-dependent inhibition of cell proliferation by PA were inverted by FA pretreatment. Phosphorylation of eNOS and expression of ER stress related genes were all inverted by FA pretreatment in PA-treated MAEC. Our findings show that fenofibrate recovers damaged EDV by chronic HFD feeding and acute stimulation of PA, this effect is related with decreased ER stress and increased phosphorylation of eNOS.

MATERIALS
Product Number
Brand
Product Description

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Supelco
Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Fenofibrate Related Compound B, United States Pharmacopeia (USP) Reference Standard
USP
Fenofibrate, United States Pharmacopeia (USP) Reference Standard
Fenofibrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Fenofibrate, ≥99%, powder